• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YU Liyan,SUN Rongmei,RAN Guimei,XIANG Bingren.Pharmacokinetic research of oral Mildronate Capsule in healthy Chinese subjects[J].Journal Of Pharmaceutical Research,2017,36(6):337-340[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 4373times   Download 3037次 QR Code for this article
Scan with your phone!
米屈肼胶囊在中国健康受试者中药代动力学的研究
于丽燕,孙荣梅,冉桂梅,相秉仁
Font:Larger+|Default|Smaller-
(中国药科大学工学院,江苏 南京 211198)
摘要:
目的 研究米屈肼胶囊在健康受试者中单次给药、多次给药的药代动力学规律。方法 采用多剂量单序列给药设计方案。12名健康受试者分别按体重由重到轻排序编号,男前女后。统一先服用低剂量250 mg(250 mg/粒×1);经清洗期后服用高剂量1 000 mg(500 mg/粒×2);再经清洗期后服用中剂量500 mg(500 mg/粒×1),并在中剂量下进行连续给药(连续给药6 d,第1~5天每日2次,第6天早上1次,每次500 mg)。结果 结果表明在250~1 000 mg剂量范围内,米屈肼呈非线性动力学特征。半衰期随着剂量增加而延长,因此多次服药后在人体内具有明显的蓄积作用。结论 本方法适合于米屈肼的人体药代动力学研究。
关键词:  米屈肼  高效液相色谱-质谱  血药浓度  药动学
DOI:10.13506/j.cnki.jpr.2017.06.008
基金项目:
Pharmacokinetic research of oral Mildronate Capsule in healthy Chinese subjects
YU Liyan,SUN Rongmei,RAN Guimei,XIANG Bingren
(Engineering Institute,China Pharmaceutical university,Nanjing 211198,China)
Abstract:
Objective To study the pharmacokinetics of mildronate capsules in healthy subjects in a single and multiple dose.Methods Using multi-dose of single-sequence for drug design,12 healthy subjects were respectively numbered according to the weight from heavy to light order number,all the female volunteers were behind the male volunteers.All the volunteers were given the low doses of 250 mg (250 mg/pill×1) medicine;After cleaning period all the volunteers were given the high doses of 1 000 mg (500 mg/pill×2) medicine;Again after cleaning period all the volunteers were given the dose 500 mg (500 mg/pill×1) medicine,and then all the volunteers were given the middle-dose of this medicine(oral drug 6 days in a row,oral this medicine twice a day from the first day to the fifth day,oral the medicine once time in the morning of the sixth day,Every time the dose is 500 mg).Results The pharmacokinetic characteristics of mildronate were nolinear pharmacokinrtics in human body.The t1/2 was prolonged with increasing does,the result of multiple dose indicated the occurrence of accumulation in the multidoses.Conclusion The method developed in this study was suitable for the pharmacokinetic study of mildronate.
Key words:  Mildronate  HPLC-MS/MS  Plasma concentration  Pharmacokinetics
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.